Nancy Merner, PhD
Department of Pathobiology
Dr. Merner pursued her graduate studies at Memorial University of Newfoundland in Canada, where her dissertation focused on the genetics of hereditary breast cancer, deafness, and a specific form of sudden cardiac death (arrhythmogenic right ventricular cardiomyopathy, or ARVC). The most significant contribution of her doctoral studies came in 2008 with the discovery of TMEM43 as the cause of ARVC type 5. Dr. Merner pursued post-doctoral training in Montreal in the laboratory of Dr. Guy Rouleau, director of the Montreal Neurological Institute at McGill University. Her primary focus was in the application of next-generation sequencing techniques for the identification of genes associated with essential tremor, autism spectrum disorder, insensitivity to pain, and epilepsy. In 2012, Dr, Merner used exome sequencing to discover the first causative ET gene, FUS. Since 2014, Dr. Merner has been a research assistant professor in the Harrison School of Pharmacy at Auburn University. With the Harrison School of Pharmacy, she established a cancer genetics research program that focuses on identifying genetic risk variants of hereditary cancer syndromes, particularly Hereditary Breast and Ovarian Cancer (HBOC) Syndrome.
HBOC susceptibility genes
Dr. Merner is continuing her quest to find HBOC susceptibility genes and incorporate a comparative genomics approach by studying both dogs and humans affected by the disease. Her program is symbolized by her big pink bus, which is known as the “Gene Machine.” The bus serves as Dr. Merner’s mobile outreach and research program that aims to engage the community through an education and trust building mechanism and offer research participation to individuals who would otherwise not have such opportunities.